Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CRISPR THERAPEUTICS AG

(CRSP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CRISPR THERAPEUTICS AG : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

10/12/2021 | 04:48pm EST

Item 7.01. Regulation FD Disclosure.

On October 12, 2021, CRISPR Therapeutics AG (the "Company") issued a press release announcing new clinical data from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of CTX110TM, its wholly-owned allogeneic chimeric antigen receptor T cell investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 7.01 of Form 8-K, including the accompanying Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

Item 8.01. Other Events

On October 12, 2021, new clinical data from the Company's ongoing Phase 1 CARBON trial assessing the safety and efficacy of CTX110 was presented at a virtual event. Selected slides from the presentation are attached hereto as Exhibit 99.2 and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits


(d) Exhibits



Exhibit
Number       Description

99.1           Press release issued by CRISPR Therapeutics AG, dated October 12,
             2021

99.2           Selected Slides from Presentation: Updated Results from the Phase 1
             CARBON Trial of CTX110™, dated October 12, 2021

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about CRISPR THERAPEUTICS AG
11/23CRISPR THERAPEUTICS : Corporate Presentation
PU
11/23CRISPR Therapeutics to Participate in Upcoming Investor Conferences
GL
11/22CRISPR Secures FDA Regenerative Medicine Advanced Therapy Status for CTX110 in B-Cell M..
MT
11/22CRISPR THERAPEUTICS : Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designat..
PU
11/22CRISPR THERAPEUTICS AG : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
11/22CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designa..
GL
11/22CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy Designation Gr..
CI
11/16CRISPR Therapeutics, ViaCyte Secure Health Canada's Approval for Clinical Trial of Diab..
MT
11/16CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited ..
GL
11/16CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited ..
CI
More news
Analyst Recommendations on CRISPR THERAPEUTICS AG
More recommendations